Literature DB >> 9738925

Interleukin-2 stimulates a late increase in phosphatidic acid production in the absence of phospholipase D activation.

D R Jones1, I Flores, E Díaz, C Martinez, I Mérida.   

Abstract

The signal transduction pathways involving phospholipid metabolism during T-cell proliferation remain partly undefined. Herein we show that interleukin-2 caused a late (> 12 h) rise in the intracellular phosphatidic acid content of CTLL-2 cells which was a consequence of the activation of the enzyme diacylglycerol kinase. No activation of phospholipase D was observed at similar times. Incubation of the cells with a recognized diacylglycerol kinase a isoform inhibitor, R59499, prior to interleukin-2 stimulation was able to block cell cycle entry, diacyglycerol kinase activation and phosphatidic acid accumulation. In contrast, when R59499 was added 3 h after interleukin-2, few or no observable effects on the above three parameters were noticed. These results suggest that the early signaling employed by IL-2 involving the alpha isoform of diacylglycerol kinase is sufficient to control the late increase in phosphatidic acid and that phosphatidic acid is a mitogenic agent in T-cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738925     DOI: 10.1016/s0014-5793(98)00875-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  2 in total

1.  A novel diacylglycerol kinase α-selective inhibitor, CU-3, induces cancer cell apoptosis and enhances immune response.

Authors:  Ke Liu; Naoko Kunii; Megumi Sakuma; Atsumi Yamaki; Satoru Mizuno; Mayu Sato; Hiromichi Sakai; Sayaka Kado; Kazuo Kumagai; Hirotatsu Kojima; Takayoshi Okabe; Tetsuo Nagano; Yasuhito Shirai; Fumio Sakane
Journal:  J Lipid Res       Date:  2016-01-14       Impact factor: 5.922

2.  Diacylglycerol kinase-dependent formation of phosphatidic acid molecular species during interleukin-2 activation in CTLL-2 T-lymphocytes.

Authors:  Satoru Mizuno; Hiromichi Sakai; Masafumi Saito; Sayaka Kado; Fumio Sakane
Journal:  FEBS Open Bio       Date:  2012-09-04       Impact factor: 2.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.